Evidence map›Paper›PMID 37457113›Full record

ArticleEClinicalMedicine2023

Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study.

Pilar Brito-Zerón, Alejandra Flores-Chávez, Ildiko Fanny Horváth, Astrid Rasmussen, Xiaomei Li, Peter Olsson, Arjan Vissink, Roberta Priori, Berkan Armagan, Gabriela Hernandez-Molina and 43 more

Open access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Activity and Damage Indices for Sjögren's Disease.Journal of clinical medicine · 2026
    Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 19 countries.

Pilar Brito-ZerónAutoimmune Diseases Unit, Research and Innovation Group in Autoimmune Diseases, Sanitas Digital Hospital, Hospital-CIMA-Centre Mèdic Milenium Balmes Sanitas, Barcelona, Spain.
Alejandra Flores-ChávezDepartment of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Spain.
Ildiko Fanny HorváthDivision of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Astrid RasmussenGenes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Xiaomei LiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China(Anhui Provincial Hosipital), Hefei, China.
Peter OlssonDepartment of Rheumatology, Skane University Hospital Malmö, Lund University, Lund, Sweden.
Arjan VissinkDepartment of Oral and Maxillofacial Surger, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Roberta PrioriDepartment of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Rome, Italy.
Berkan ArmaganDivision of Rheumatology, Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
Gabriela Hernandez-MolinaImmunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico.
Sonja PraprotnikDepartment of Rheumatology, University Medical Centre, Ljubljana, Slovenia.
Luca QuartuccioClinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy.
Nevsun InançMarmara University, School of Medicine, Istanbul, Turkey.
Burcugül ÖzkızıltaşDivision of Rheumatology, Department of Internal Medicine, Gazi University School of Medicine, Ankara, Turkey.
Elena BartoloniRheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy.
Agata SebastianDepartment of Rheumatology and Internal Medicine, Wroclaw Medical Hospital, Wroclaw, Poland.
Vasco C RomãoRheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte and Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon Academic Medical Centre, Lisbon, Portugal.
Roser SolansDepartment of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain.
Sandra G PasotoRheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
Maureen RischmuellerDepartment of Rheumatology, The Queen Elizabeth Hospital, Discipline of Medicine, University of Adelaide, South Australia, Australia.
Carlos GalisteoDepartment of Rheumatology, Hospital Parc Taulí, Barcelona, Spain.
Yasunori SuzukiDivision of Rheumatology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Virginia Fernandes Moça TrevisaniDivision of Health Based Evidence, Federal University of São Paulo, Sao Paulo, Brazil.
Cecilia FugmannRheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Andrés González-GarcíaDepartment of Rheumatology, Hospital 12 de Octubre, Madrid, Spain.
Francesco CarubbiInternal Medicine and Nephrology Unit, Department of Medicine, ASL Avezzano-Sulmona-L'Aquila, San Salvatore Hospital, L'Aquila, Italy.
Ciprian JurcutDepartment of Internal Medicine, Carol Davila Central Military Emergency Hospital, Bucharest, Romania.
Toshimasa ShimizuDivision of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Soledad RetamozoDepartment of Rheumatology, Hospital Quirón Salud, Barcelona, Spain.
Fabiola AtzeniIRCCS Galeazzi Orthopedic Institute, Milan and Rheumatology Unit, University of Messina, Messina, Italy.
Benedikt HofauerOtorhinolaryngology, Head and Neck Surgery, Technical University Munich, Munich, Germany.
Sheila Melchor-DíazDepartment of Rheumatology, Hospital 12 de Octubre, Madrid, Spain.
Tamer GheitaRheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt.
Miguel López-DuplaDepartment of Internal Medicine, Hospital Joan XXIII, Tarragona, Spain.
Eva Fonseca-AizpuruDepartment of Internal Medicine, Hospital de Cabueñes, Gijón, Spain.
Roberto GiacomelliClinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy.
Marcos VázquezDepartment of Rheumatology, Hospital de Clínicas, San Lorenzo, Paraguay.
Sandra ConsaniInternal Medicine, Hospital Maciel, and Universidad de la República (UdelaR), Montevideo, Uruguay.
Miriam AkasbiDepartment of Internal Medicine, Hospital Infanta Leonor, Madrid, Spain.
Hideki NakamuraDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Oyaguchi Kami-cho, Itabashi-ku, Tokyo, Japan.
Antónia SzántóDivision of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
A Darise FarrisGenes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Li WangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China(Anhui Provincial Hosipital), Hefei, China.
Thomas MandlDepartment of Rheumatology, Skane University Hospital Malmö, Lund University, Lund, Sweden.
Angelica GattamelataDepartment of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Rome, Italy.
Levent KilicDivision of Rheumatology, Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
Katja Perdan PirkmajerDepartment of Rheumatology, University Medical Centre, Ljubljana, Slovenia.
Kerem AbacarMarmara University, School of Medicine, Istanbul, Turkey.
Abdurrahman TufanDivision of Rheumatology, Department of Internal Medicine, Gazi University School of Medicine, Ankara, Turkey.
Salvatore de VitaClinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy.
Hendrika BootsmaDepartment of Rheumatology & Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Manuel Ramos-CasalsDepartment of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Spain.
Sjögren Big Data Consortium
Universidad de la República de Uruguay · UYLjubljana University Medical Centre · SIOspedale Santa Maria della Misericordia di Udine · ITUniversity Medical Center Groningen · NLHospital Clínic de Barcelona · ESResearch Institute Hospital 12 de Octubre · ESUniversity of Science and Technology of China · CNGazi University · TRHacettepe University · TRLund University · SEMarmara University · TROklahoma Medical Research Foundation · USUniversity of Debrecen · HUUniversity of L'Aquila · ITCairo University · EGCarol I National Defence University · ROCentro Médico Sanitas Balmes · ESCorporació Sanitària Parc Taulí · ESHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRHospital de Clínicas · UY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: What baseline predictors would be involved in mortality in people with primary Sjögren syndrome (SjS) remains uncertain. This study aimed to investigate the baseline characteristics collected at the time of diagnosis of SjS associated with mortality and to identify mortality risk factors for all-cause death and deaths related to systemic SjS activity measured by the ESSDAI score. Methods: In this international, real-world, retrospective, cohort study, we retrospectively collected data from 27 countries on mortality and causes of death from the Big Data Sjögren Registry. Inclusion criteria consisted of fulfilling 2002/2016 SjS classification criteria, and exclusion criteria included chronic HCV/HIV infections and associated systemic autoimmune diseases. A statistical approach based on a directed acyclic graph was used, with all-cause and Sjögren-related mortality as primary endpoints. The key determinants that defined the disease phenotype at diagnosis (glandular, systemic, and immunological) were analysed as independent variables. Findings: Between January 1st, 2014 and December 31, 2023, data from 11,372 patients with primary SjS (93.5% women, 78.4% classified as White, mean age at diagnosis of 51.1 years) included in the Registry were analysed. 876 (7.7%) deaths were recorded after a mean follow-up of 8.6 years (SD 7.12). Univariate analysis of prognostic factors for all-cause death identified eight Sjögren-related variables (ocular and oral tests, salivary biopsy, ESSDAI, ANA, anti-Ro, anti-La, and cryoglobulins). The multivariate CPH model adjusted for these variables and the epidemiological features showed that DAS-ESSDAI (high vs no high: HR = 1.68; 95% CI, 1.27-2.22) and cryoglobulins (positive vs negative: HR = 1.72; 95% CI, 1.22-2.42) were independent predictors of all-cause death. Of the 640 deaths with available information detailing the specific cause of death, 14% were due to systemic SjS. Univariate analysis of prognostic factors for Sjögren-cause death identified five Sjögren-related variables (oral tests, clinESSDAI, DAS-ESSDAI, ANA, and cryoglobulins). The multivariate competing risks CPH model adjusted for these variables and the epidemiological features showed that oral tests (abnormal vs normal results: HR = 1.38; 95% CI, 1.01-1.87), DAS-ESSDAI (high vs no high: HR = 1.55; 95% CI, 1.22-1.96) and cryoglobulins (positive vs negative: HR = 1.52; 95% CI, 1.16-2) were independent predictors of SjS-related death. Interpretation: The key mortality risk factors at the time of SjS diagnosis were positive cryoglobulins and a high systemic activity scored using the ESSDAI, conferring a 2-times increased risk of all-cause and SjS-related death. ESSDAI measurement and cryoglobulin testing should be considered mandatory when an individual is diagnosed with SjS. Funding: Novartis.

Indexed as

CardiovascularInfectionLymphomaMortalitySjögren syndromeSystemic disease

Identifiers

PMID37457113
PMCPMC10344811
OpenAlexW4383101080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.